List of select companies cited in the 1st Edition of our Next Generation Sequencing (NGS) ReportToday, DeciBio announces the release of a next generation sequencing (NGS) / third generation sequencing (3GS) report. “Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider” is a comprehensive review of the NGS market to date.Next generation sequencing (NGS) is a disruptive technology that allows scientists to sequence millions to billions of short DNA reads for a variety of applications such as whole genome sequencing, genotyping, or expression profiling. NGS is the fastest growing and the most attractive segments of the $6.5B genomics space. With an estimated market size of ~$1.1B in 2011, and a double digit growth rate, NGS is poised to revolutionize not only medical research in academic laboratories and biopharma, but also the healthcare landscape and applied markets (e.g., food testing, forensics).This report reviews the market size, segmentation, growth and trends of the NGS and third generation sequencing (3GS) market. We segmented the market by company (Illumina, Life Technologies, Roche,Pacific BioSciences, Helicos, Complete Genomics, others), product types (instrument, reagents, services), research setting (research, biopharma, applied markets and clinical), throughput (high and low) and geography (U.S., Europe, Asia/Pacific, ROW). For each of these segments, we provide an estimate yearly market size and growth from 2007 to 2015, as well as key drivers and moderators of this growth.This report cites a number of additional companies participating in the NGS space, including:

• Large genome centers (e.g., Broad Institute of MIT and Harvard, Baylor College of Medicine’s Human Genome Center, Genome Center at Washington U., Wellcome Trust Sanger Institute,BGI, Craig Venter Institute and Joint Genome Institute) and other companies offering sequencing services (e.g., Perkin Elmer)
• Sample enrichment companies (e.g., Agilent, Roche NimbleGen, Fluidigm, Raindance,FlexGen),
• Clinical sequencing companies (e.g., GeneDx, Correlagen, Ambry Genetics, National Center for Genome Resources (NCGR), Axeq Technologies, Verinata (formerly Artemis Health),LifeCodexx, Good Start Genetics, Foundation Medicine, Pathogenica, Sundance Diagnostics, MLC Diagnostics, Adaptive TCR Technologies
• Companies with novel technologies (Oxford Nanopore Technologies, LaserGen, Intelligent Bio-Systems, OpGen, Otogenetics, GnuBIO, StarLight (Life Technologies), NABsys, BioNanomatrix,Halcyon Molecular, NobleGen Biosciences, Electronic Biosciences, Stratos Genomics, Electron Optica, Caerus Molecular Diagnostics, Rubicon Genomics, IntegenX, Polony sequencing, IBM,GenapSys)
• NGS bioinformatics companies: GenoLogics , DNAnexus, Cycle Computing, Omicia, Station X,Xcelris genomics, Personalis, Accelrys, Golden Helix

Authors: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel